Countries seeking their own COVID-19 vaccine doses are making deals with drug companies that threaten the supply for the global COVAX program for poor and middle-income countries, the World Health Organization said on Feb. 26.
San Diego-based Janux Therapeutics forged a strategic collaboration with pharma giant Merck potentially worth more than $1 billion to develop next-generation T cell engager immunotherapies for the treatment of cancer.
Dragonfly Therapeutics announced a new research collaboration with Bristol Myers Squibb to discover and develop Dragonfly’s novel immunotherapies for multiple sclerosis and neuro-inflammation targets.
The Department of Justice leveled more charges against members of the U.S. science community who have alleged ties to China.
Nearly one year after charges were filed against former Genentech employees accused of stealing trade secrets to benefit Taiwan-based biosimilar drugmaker JHL Biotech, the two companies reached an agreement over the ill-gotten intellectual property – destruction.
